Post by Deleted on Dec 12, 2016 19:10:46 GMT
OPKO HEALTH
NASDAQ:
OPK
Industry:
Pharmaceuticals
SABRIENT
STRONG
BUY
RATING
Report prepared on
August 23, 2016
Page
1
Please see important disclaimer on page
4 of this report.
Copyright ©2016 Sabrient Systems LLC. All rights reserved.
Sabrient
Leaders In Investment Research
Stock Fundamentals
as of August 22, 2016
Sabrient Rating
Strong Buy
Ticker
OPK
Market Cap Designation
Mid-cap
Market Capitalization (Billions)
$5.4
Price
$9.80
52-Week High/Low
$11.60/7.66
EPS (TTM)
$0.28
P/E Ratio (TTM)
35.3
Dividend Yield
0.0%
Price/Book Ratio
2.7
Price/Sales Ratio
5.1
30-Day Average Volume (Millions)
2.5
Beta
1.85
Current Ratio
1.7
Short Interest Ratio
N/A
Shares Outstanding (Millions)
550.4
Sabrient Ratings
Sabrient's Buy/Hold/Sell ratings are based on a
combination of dynamic filters that determine which
attributes of a stock are most predictive in the prevailing
market and which stocks best reflect those attributes but
are not yet rewarded.
Sabrient starts with an "extraction" process that uses the
best performing filters to identify stocks having certain
compelling attributes currently sought by the market.
Then, a composite scoring process uses a weighted
average of several key scores to quantify the relative
likelihood of upside or downside price action. As a result,
the Buy/Hold/Sell rating may, in certain cases, seem
inconsistent with a simple average of the scores cited in
this analysis.
A BUY rating means the stock is expected to outperform
its relevant benchmark substantially over the next 6
months. A SELL rating means the stock is expected to
underperform its relevant benchmark substantially over
the next 6 months. A HOLD rating means the stock is
expected to perform in line with its relevant benchmark
over the next 6 months.
If a stock is rated HOLD, the investor should review
the stock's history of Sabrient ratings to see if it has
recently changed to HOLD from BUY or SELL. If so, this
indicates one of the following: (1) there has been a
significant change in the stock's fundamentals, (2) the
stock is already appropriately rewarded or punished by
the market, or (3) there simply has been some recent
price consolidation that warrants attention. A reading of
Sabrient's analysis should identify which it is.
More about Sabrient on Page
3
Sabrient's Market Cap Designations
Large Cap
> $5.0 Billion
Mid Cap
$1.0 - $5.0 Billion
Small Cap
$150 Million - $1.0 Billion
Micro Cap
< $150.0 Million
Sep '15
Oct
Nov
Dec
Jan '16
Feb
Mar
Apr
May
Jun
Jul
Aug
$8
$9
$10
$11
5
10
OPKO HEALTH
Average Daily Volume
in Millions
50-Day Moving Average
Company Profile
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through
two segments: diagnostics and pharmaceutical. The pharmaceutical segment
consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain,
and its pharmaceutical research and development operations. The diagnostics
segment primarily consists of its clinical laboratory operations.
Earnings and Revenue Update:
For the quarter ended June 30, 2016, OPKO Health
Inc reported earnings of $15.5 million or $0.03 per share compared with $-12.0
million for the prior quarter and $-42.8 million or $-0.09 per share for the same
quarter one year ago. Revenues were $357.1 million for the quarter ended June
30, 2016 compared with $291.0 million for the prior quarter and $42.4 million for
the same quarter one year ago. Last twelve months' earnings were $0.28 per share
compared with $-0.59 per share a year ago. Last twelve months' revenues were $1.1
billion compared with $117.8 million a year ago.
Sabrient Analysis
OPK earns a Strong Buy rating, despite modest scores for value, growth and
momentum. Based on Sabrient's composite filtering process, the stock offers a
combination of attributes being rewarded by today's market.
• Growth:
With a Sabrient Growth Score of 55.2, OPK would be an average, rather
than ideal, candidate for investors seeking a good growth stock. The outlook could
change if the company achieves a quarter or two of improved results or if analysts
find reason to revise their estimates upward.
• Value:
With a Sabrient Value Score of 51.2, OPK appears to be fairly valued at its
current price and earnings trends.
• Momentum:
A Sabrient Momentum Score of 31.3 means OPK has a below-average
rating for a composite measure of price, earnings and group momentum.
• Timeliness:
OPK has a Sabrient Timeliness Score of 32.6. This is a composite
measure of short-term and long-term price performance and long-term group
performance.
Sabrient Analysis continued on Page 3
OPKO HEALTH
NASDAQ:
OPK
Industry:
Pharmaceuticals
SABRIENT
STRONG
BUY
RATING
Report prepared on
August 23, 2016
Page
2
Please see important disclaimer on page
4 of this report.
Copyright ©2016 Sabrient Systems LLC. All rights reserved.
Sabrient
Leaders In Investment Research
Current Sabrient Scores Compared with Industry and Relevant Benchmark
These Sabrient scores compare various aspects of OPKO HEALTH with its industry and relevant benchmarks. The scores are percentile rankings from 0 to 99.9. Higher scores are
better. We use a weighted average of several key scores to quantify the relative likelihood of upside or downside price action. Therefore, the Sabrient rating may seem inconsistent
with a simple average of the scores cited in this analysis.
Growth Score: 55.2
Very Low
Low
Average
High
Very High
OPK
55.2
Industry
53.6
sp400
47.8
The Sabrient Growth Score reflects a company's historical and projected earnings
growth, revenue and sales growth, projected cash flow, analyst activity, and changes in
earnings estimates, each over various time periods. The higher the score, the better the
combined performance of these key measures. With a Sabrient Growth Score of 55.2,
OPKO Health Inc is in line with the average of its industry group, which has a Sabrient
Growth Score of 53.6.
Value Score: 51.2
Very Low
Low
Average
High
Very High
OPK
51.2
Industry
42.5
sp400
44.2
The Sabrient Value Score measures the relationship between a company's stock price
and its intrinsic value, as indicated by earnings and balance sheet attributes, with
an emphasis on earnings. Also considered are cash flow measures and fundamental
valuation ratios. With a Sabrient Value Score of 51.2, OPKO Health Inc is marginally
higher than the average of its industry group, which has a Sabrient Value Score of 42.5.
Momentum Score: 31.3
Very Low
Low
Average
High
Very High
OPK
31.3
Industry
33.8
sp400
50.8
The Sabrient Momentum Score measures a company's earnings and price momentum,
evenly weighted, and augmented by group strength, money flow, and relative volume.
Core technical factors include current price relative to periodic highs and moving
averages. With a Sabrient Momentum Score of 31.3, OPKO Health Inc is marginally lower
than the average of its industry group, which carries a Sabrient Momentum Score of
33.8.
Earnings Score: 21.4
Very Low
Low
Average
High
Very High
OPK
21.4
Industry
52.8
sp400
45.6
The Sabrient Earnings Score assesses a company's overall earnings performance
and projected outlook. Time periods include an average look-back of three years with
an emphasis on the past four quarters and a forward look of one to five years. With
a Sabrient Earnings Score of 21.4, OPKO Health Inc is well below the average of its
industry group, which has a Sabrient Earnings Score of 52.8.
Balance Sheet Score: 57.5
Very Low
Low
Average
High
Very High
OPK
57.5
Industry
55.6
sp400
53.8
The Sabrient Balance Sheet Score measures a company's liquidity and debt issues,
as well as receivables and inventory quality. This score is used to assess relative risk
associated with a stock: the lower the score, most likely the higher the inherent risk.
With a Sabrient Balance Sheet Score of 57.5, OPKO Health Inc is in line with the average
of its industry group, which carries a Sabrient Balance Sheet Score of 55.6.
Fundamental Score: 23.1
Very Low
Low
Average
High
Very High
OPK
23.1
Industry
43.8
sp400
52.4
The Sabrient Fundamental Score is the broad measure of a company's financial health,
including its balance sheet, cash flow, revenue, and earnings quality. With a Sabrient
Fundamental Score of 23.1, OPKO Health Inc is considerably lower than the average of
its industry group, which carries a Sabrient Fundamental Score of 43.8.
Timeliness Score: 32.6
Very Low
Low
Average
High
Very High
OPK
32.6
Industry
48.2
sp400
50.2
The Sabrient Timeliness Score is an assessment of a stock's short and long-term price
strength as determined by various chart-based indicators and measures of group
momentum and relative price performance. With a Sabrient Timeliness Score of 32.6,
OPKO Health Inc is moderately lower than the average of its industry group, which
carries a Sabrient Timeliness Score of 48.2.
Peer Analysis
This table compares OPK with other similar-sized companies in the same industry group, focusing on Sabrient's growth, momentum and value scores, which represent the three
main investing styles. The Peer Analysis chart compares OPK's 2-year total return with the average 2-year total return of these companies.
2-Year Total Return
2015
2016
-25%
25%
50%
75%
100%
OPK
Peers
Symbol
Company
Growth Score
Momentum Score
Value Score
Market Cap.(M)
OPK
OPKO HEALTH
55.2
31.3
51.2
$5410.2
AKRX
Akorn Inc
75.4
23.7
44.2
$0.0
ENDP
Endo International PLC
59.7
63.8
97.0
$0.0
TARO
Taro Pharmaceutical Industries Ltd
67.6
18.9
82.0
$0.0
HZNP
Horizon Pharma PLC
76.6
73.9
60.8
$0.0
CTLT
Catalent Inc
10.1
34.0
64.2
$0.0
PTHN
Patheon NV
52.5
22.0
63.2
$0.0
OPKO HEALTH
NASDAQ:
OPK
Industry:
Pharmaceuticals
SABRIENT
STRONG
BUY
RATING
Historical Sabrient Scores
The recent histories of key Sabrient scores provide insight
into the stock's trends -- whether they are increasing
or decreasing in strength in a particular area or simply
holding steady. The Sabrient scores are percentile
rankings from 0 to 99.9, with higher scores better. Keep
in mind that Sabrient ratings may seem inconsistent with
a simple average of these key scores because a weighted
average of several key scores is used to quantify the
relative likelihood of upside or downside price action.
Growth Score: 55.2
8/18/15
2/23/16
5/17/16
Current
20
40
60
80
100
60.0
71.2
63.7
55.2
Value Score: 51.2
8/18/15
2/23/16
5/17/16
Current
20
40
60
80
100
39.8
37.4
19.5
51.2
Momentum Score: 31.3
5/17/16
6/21/16
7/19/16
Current
20
40
60
80
100
43.6
18.8
48.9
31.3
Earnings Score: 21.4
8/18/15
2/23/16
5/17/16
Current
20
40
60
80
100
68.4
55.1
27.0
21.4
Balance Sheet Score: 57.5
8/18/15
2/23/16
5/17/16
Current
20
40
60
80
100
54.8
52.0
51.8
57.5
Fundamental Score: 23.1
8/18/15
2/23/16
5/17/16
Current
20
40
60
80
100
3.6
3.9
8.4
23.1
Timeliness Score: 32.6
5/17/16
6/21/16
7/19/16
Current
20
40
60
80
100
36.1
23.9
38.1
32.6
Report prepared on
August 23, 2016
Page
3
Please see important disclaimer on page
4 of this report.
Copyright ©2016 Sabrient Systems LLC. All rights reserved.
Sabrient
Leaders In Investment Research
Sabrient Analysis continued from Page 1
• Best Performing Filters:
To determine the likelihood of near-term performance,
Sabrient builds and backtests "Smart Filters" to establish which caps, styles and
attributes are drawing a premium in today's market. Currently, the three most
predictive filters for the relevant segment are:
•
Price Trend Filter:
The Price Trend Filter uses a sophisticated statistical analysis
to evaluate a stock's current price with respect to its long-term trend and to
compare the result to the stock's core growth charateristics. A high score
means the stock is below its long-term trend, especially in light of its earnings
performance. A low score means the stock is above its long-term trend and
may likely fall back to or below the mean. As of last month, this filter showed a
substantial premium to its mid-cap benchmark. OPK scores 88.5 for this filter.
•
Momentum Rank Change Filter:
The Momentum Rank Change Filter measures
short-term changes among key momentum measures, including earnings, price
and group momentum. During the past 90 days, the filter outperformed its
mid-cap benchmark by a substantial margin. OPK scores 9.1 for this filter.
•
Analysts Change Filter:
The Analysts' Change Filter assesses recent revisions
in the analysts' earnings estimates. At the end of last month, the filter posted an
exceptional premium to its mid-cap benchmark. OPK scores 25.0 for this filter.
In summary, OPK's Strong Buy rating is based on a profile of forward-looking
metrics which show this stock could significantly outperform the broader markets.
What the Market Wants: July 2015
To read this week's "What the Market Wants" go to the Sabrient Blog at
www.sabrient.com/blog/
Company Description
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates
through two segments: diagnostics and pharmaceutical. The pharmaceutical
segment consists of its pharmaceutical operations in Chile, Mexico, Ireland,
Israel and Spain, and its pharmaceutical research and development operations.
The diagnostics segment primarily consists of its clinical laboratory operations.
The Companys diagnostics business includes Bio-Reference Laboratories
(Bio-Reference), which is a clinical laboratory with a genetic testing business,
including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay
platform. Its pharmaceutical business includes OPKO Biologics, which features
hGH-CTP, a once-weekly human growth hormone injection (in Phase III and
partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase
IIa). In addition to its pharmaceutical and diagnostic development programs, it
owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.
About Sabrient
Sabrient Systems is an independent research firm providing statistical analysis
of a company's fundamental data to investment professionals. We use a
computer-driven, quantitative methodology to identify stocks that appear poised to
outperform or underperform the market.
OPKO HEALTH
NASDAQ:
OPK
Industry:
Pharmaceuticals
SABRIENT
STRONG
BUY
RATING
Report prepared on
August 23, 2016
Page
4
Please see important disclaimer on page
4 of this report.
Copyright ©2016 Sabrient Systems LLC. All rights reserved.
Sabrient
Leaders In Investment Research
The Sabrient methodology was developed by an experienced research team led by David Brown, a former NASA scientist and
retired CEO of Telescan and designer of its premier stock search program, ProSearch. The research team employs a scientific
approach to the creation and testing of multi-factor filters. Each filter targets a key area of traditional stock analysis, including
value, growth, momentum, fundamentals, earnings, balance sheet, and group strength. Using an adaptive process, filters are
continually tested and monitored to ensure that only the best performing filters are at work.
Sabrient's ratings begin with an extraction process in which each of the few best-performing filters scans the universe of
equities to identify stocks having certain compelling attributes sought, but not sufficiently rewarded, by the current market.
Then, a composite scoring system employs a broader set of "weighting" filters to rank the extracted stocks. To support
individual investors, Sabrient uses the same sophisticated methodology to provide individual stock reports on a universe of
approximately 5,600 stocks.
Sabrient regularly tests the performance of its stock selections, using its primary list of published rankings and statistical
techniques it believes appropriate. These recommendations have consistently outperformed relevant benchmarks across a
broad range of investing styles, market caps, time frames and market conditions, demonstrating the robustness of Sabrient's
proprietary methodology. While past performance is no guarantee of future results, Sabrient believes it can maintain its strong
performance through its rigorous, scientific approach to filter construction and ongoing backtesting within a dynamic and
adaptive composite scoring system.
For more information on Sabrient and its performance, go to
www.sabrient.com
Disclaimer
Sabrient SmartStock™ research is provided for informational purposes only. It is neither a solicitation to buy nor an offer to sell these securities. The report is
based upon data from sources believed to be reliable, but Sabrient makes no representation as to the data's adequacy, accuracy, completeness or timeliness.
The report does not address individual investment objectives or financial situations. The analysis used in preparing these reports may also be used in the
preparation of other research products which may reflect distinct investment objectives. Sabrient accepts no liability for any loss arising from any use of this
report.
This report is based solely on mathematical calculations and does not reflect any bias of individual analysts. Sabrient provides no investment banking, consulting
or other services to the subject company of this report. No Sabrient employee is on the Board of Directors of the subject company, and no one at the subject
company serves on the Board of Directors of Sabrient Systems. Sabrient or its employees may have long or short positions in the securities or other related
investments of the company mentioned herein, but never more than one percent (1%) of the outstanding shares of any company covered by Sabrient. No part of
this document may be reproduced without the written permission of Sabrient Systems.
=======================================
C L